Rapid Biopharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 19-12-2024
- Paid Up Capital ₹ 6.20 M
as on 19-12-2024
- Company Age 13 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Revenue 52.89%
(FY 2020)
- Profit 12.16%
(FY 2020)
- Ebitda 183.99%
(FY 2020)
- Net Worth 2.30%
(FY 2020)
- Total Assets 2.16%
(FY 2020)
About Rapid Biopharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 6.20 M, as per Ministry of Corporate Affairs (MCA) records.
Dasagrandhi Harinath, Vijaya Gooty, Dasagrandhi Madhuri, and One other member serve as directors at the Company.
- CIN/LLPIN
U24232KA2011PTC060979
- Company No.
060979
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
31 Oct 2011
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangaluru, Karnataka, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Rapid Biopharma Private Limited offer?
Rapid Biopharma Private Limited offers a wide range of products and services, including TB, Tumor & Cancer Drugs, Anti Cancer Medicines, Oncology Drug.
Who are the key members and board of directors at Rapid Biopharma?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Dasagrandhi Madhuri  | Director | 25-Mar-2015 | Current |
| Dasagrandhi Harinath | Director | 31-Oct-2011 | Current |
| Vijaya Gooty | Director | 10-Apr-2015 | Current |
| Dasagranthi Kumar | Director | 10-Apr-2015 | Current |
Financial Performance of Rapid Biopharma.
Rapid Biopharma Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 52.89% increase. The company also saw a substantial improvement in profitability, with a 12.16% increase in profit. The company's net worth moved up by a moderate rise of 2.3%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Rapid Biopharma?
In 2019, Rapid Biopharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Rapid Biopharma?
Unlock and access historical data on people associated with Rapid Biopharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Rapid Biopharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Rapid Biopharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
